This mechanism of adjuvant-induced DC migration has the potential to help expand tumor-specific T cells in the TdLN, contributing to the CD8 T cell-dependent control of tumors treated with RT and VIR3 following the return of T cells to the irradiated tumor. Here, CD8A is linked to neoplasm.